[Expression of adhesion molecules on lymphocyte in patients with systemic lupus erythematosus] NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Expression of adhesion molecules on lymphocyte in patients with systemic lupus erythematosus]

Chung Hua Nei Ko Tsa Chih. 1995 Aug;34(8):545-7. Unique Identifier : AIDSLINE MED/96329755
Zhou T; Jiang Y; Yao J; Ruijin Hospital, Shanghai Second Medical University.

Abstract: Peripheral blood lymphocyte phenotype (CD3, CD4, CD8, CD20, CD45RA and CD45RO) and adhesion molecule phenotype (CD11a/LFA-1 alpha, CD18/LFA-1 beta and CD54/ICAM-1) were investigated in 35 patients with systemic lupus erythematosus (SLE) by using flow cytometric analysis and dual immunofluorescence staining method. Results demonstrated increase in CD8+ cell and decrease in CD4+ cell, CD4+/CD8+, and CD4+/CD45RA+ cell, as well as decrease in expression of CD11a and CD18 on CD4+ cell surface, Expression of CD11a and CD18 on CD8+ cell, and CD54 on CD20+ cell increased, Moreover, increase in CD18 on CD8+ cell correlated inversely with decrease in CD4+ CD45RA+ cell (P < 0.05) and positively with increase in CD54 on CD20+ cell (P < 0.01). These data suggest that adhesion molecule LFA-1 and ICAM-1 may play an important role in the pathogenesis of SLE.
Keywords: Adolescence Adult Antigens, CD18/BLOOD Antigens, CD45/BLOOD CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY English Abstract Female Flow Cytometry Fluorescent Antibody Technique Human Intercellular Adhesion Molecule-1/*BLOOD Lupus Erythematosus, Systemic/*IMMUNOLOGY Lymphocyte Function-Associated Antigen-1/*BLOOD Male Middle Age Support, Non-U.S. Gov't T-Lymphocyte Subsets/*IMMUNOLOGY JOURNAL ARTICLE
961130
M96B1835

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .